Featured Research

from universities, journals, and other organizations

Biochemists Gain Crystal-Clear Insight Into 'Ancient' Enzyme

Date:
May 15, 1998
Source:
Duke University
Summary:
Biochemists from the University of Pennsylvania and Duke University Medical Center have reported analytical studies revealing unexpected new insights into how two very different molecules - a protein and an RNA - work together to form an enzyme that performs one of the fundamental tasks of constructing the protein-making machinery of the cell.

DURHAM, N.C. -- Biochemists from the University of Pennsylvania and Duke University Medical Center have reported analytical studies revealing unexpected new insights into how two very different molecules - a protein and an RNA - work together to form an enzyme that performs one of the fundamental tasks of constructing the protein-making machinery of the cell.

Their findings suggest that the partnership between the two molecules might represent an ancient remnant of an early era in life's evolution when RNA molecules were the enzymatic workhorses of primordial cells, before more versatile proteins evolved to take over the job.

The findings also may offer new targets for antibiotic compounds that could disrupt this key process in bacteria to kill them, the researchers said.

The biochemists reported in the May 1 issue of Science that they had obtained the crystal structure of the protein that is part of the enzyme "ribonuclease P." This enzyme is also known as a "ribozyme," because it is one in which the ribonucleic acid (RNA) functions as a catalyst.

Reporting their work were graduate student Travis Stams and Professor David Christianson of the University of Pennsylvania chemistry department; and Duke Medical Center postdoctoral fellow S. Niranjanakumari and Carol Fierke, associate professor of biochemistry. Their work is supported by the National Institutes of Health.

Ribonuclease P plays a key role in activating a molecule called transfer-RNA (tRNA) after it is first synthesized. Such tRNA molecules are the cellular equivalent of errand boys, latching onto individual subunits of proteins, called amino acids, to carry them to the cell's protein-making machinery, where the amino acids are chemically attached to one another in long stringlike molecules that fold into the cell's working proteins.

Specifically, ribonuclease P is a molecular scissors that helps turn a newly synthesized precursor into a functioning tRNA molecule by snipping off an extraneous segment at one end of the "pre-tRNA" molecule. Similarly, ribonuclease P helps activate another RNA, called ribosomal RNA, that is central to the cell's protein-making machinery.

In their experiments, the University of Pennsylvania researchers produced crystals of the ribonuclease P protein, and obtained the protein's structure through the widely used analytical method of X-ray crystallography. In this technique, an X-ray beam is directed through the protein crystal and is diffracted by the crystal's atoms into a pattern of spots. By analyzing the pattern, chemists can deduce the structure of the protein molecules that make up the crystal.

In analyzing the protein's structure, the biochemists found three regions where the protein could bind RNA. One region had an unusual topology and chemical characteristics that suggested it could be the place where the protein bound the RNA portion of the ribonuclease P enzyme.

However, another RNA-binding region of the protein consisted of a large cleft whose characteristics suggested it grabbed and held the segment of the pre-tRNA that was to be snipped off to produce the functioning tRNA.

These findings were particularly surprising, said the chemists, because most theories held that such proteins played only a structural role, helping fold the RNA into its active form, and not an active role in the catalytic chemical reaction.

"Before we had the structure, we had demonstrated that the protein was very important for binding of the pre-tRNA substrate," Fierke said, "but it wasn't important for binding tRNA. This binding could have been either an indirect effect, like changing the conformation of the RNA, or a direct effect. And in general it's been believed such proteins were only involved in folding the RNA, and not really involved in catalysis.

"But these data suggest that the end of the pre-tRNA snakes through that cleft, with the protein directly contacting the pre-tRNA. This is really a very different mechanism for what these proteins do," said Fierke.

The Duke researchers performed chemical experiments that confirmed this contact, producing altered versions of the protein that would chemically cross-link with the RNA in the cleft, allowing them to unequivocally determine that the protein was holding the RNA.

The Duke researchers also are tinkering with the protein's structure to explore a potential third key RNA binding region on the protein that may help the RNA of the ribonuclease P grab magnesium atoms that it needs to function optimally.

Such findings may offer intriguing insights into how the machinery of living cells first evolved, Fierke said.

"We really didn't expect such a role for the protein," she said. "And, if it turns out to be true, one could speculate that one of the reasons life evolved from an RNA-dependent world to a protein-dependent world is that the RNA required magnesium to do anything. And RNA is not particularly good at forming specific metal binding sites, whereas proteins are particularly good."

The biochemists' work might offer new targets for antibiotics, since ribonuclease P is essential for making all tRNAs, and since the bacterial enzyme is different from the enzyme in higher organisms. Thus, both the Duke and University of Pennsylvania groups propose to design inhibitor compounds that will block some aspect of the critical contacts among the protein, the RNA portion of the ribozyme, and the pre-tRNA.

"There are a great many places one could target to thwart this enzyme," Fierke said.


Story Source:

The above story is based on materials provided by Duke University. Note: Materials may be edited for content and length.


Cite This Page:

Duke University. "Biochemists Gain Crystal-Clear Insight Into 'Ancient' Enzyme." ScienceDaily. ScienceDaily, 15 May 1998. <www.sciencedaily.com/releases/1998/05/980515080552.htm>.
Duke University. (1998, May 15). Biochemists Gain Crystal-Clear Insight Into 'Ancient' Enzyme. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/1998/05/980515080552.htm
Duke University. "Biochemists Gain Crystal-Clear Insight Into 'Ancient' Enzyme." ScienceDaily. www.sciencedaily.com/releases/1998/05/980515080552.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins